Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context

OBJECTIVES: The aim of this study was to describe virological outcomes in people with HIV (PWH) after discontinuation of long-acting (LA) cabotegravir (CAB) plus rilpivirine (RPV). METHODS: All PWH enrolled in the Icona Cohort who discontinued CAB/RPV LA and had at least one follow-up after discontinuation were included. RESULTS: A total of 84 out of 805 (10.4%) PWH discontinued CAB/RPV, mainly due to toxicity or adverse events (67.9%). Most individuals (72.6%) returned to the same oral antiretroviral regimen used prior LA therapy. The 12-month cumulative probability of discontinuing oral ART after CAB/RPV was 19.9% (95% confidence interval [CI] 11.9-32.2%). After switching back to oral ART all individuals except one maintained or achieved HIV RNA levels below 50 copies/mL. CONCLUSION: These findings suggest that PWH who discontinue LA CAB/RPV and resume oral ART maintain or achieve high rates of virologic suppression.

Authors

Institutions

Publication Details

Journal
International Journal of Infectious Diseases
Published
2026-04-15
DOI
https://doi.org/10.1016/j.ijid.2026.108704
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context

Roberta Gagliardini, Alessandro Tavelli, Angelo Roberto Raccagni, Nicholas Brian Bana et al.
International Journal of Infectious Diseases
HIV/AIDS drug development and treatment
article

Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context

Roberta Gagliardini, Alessandro Tavelli, Angelo Roberto Raccagni, Nicholas Brian Bana, Nicola Squillace, Antonella d'Arminio Monforte, Giulia Marchetti, Annalisa Saracino, Valentina Mazzotta, Andrea Antinori, Camilla Muccini, Andrea Giacomelli
article en

Abstract

OBJECTIVES: The aim of this study was to describe virological outcomes in people with HIV (PWH) after discontinuation of long-acting (LA) cabotegravir (CAB) plus rilpivirine (RPV). METHODS: All PWH enrolled in the Icona Cohort who discontinued CAB/RPV LA and had at least one follow-up after discontinuation were included. RESULTS: A total of 84 out of 805 (10.4%) PWH discontinued CAB/RPV, mainly due to toxicity or adverse events (67.9%). Most individuals (72.6%) returned to the same oral antiretroviral regimen used prior LA therapy. The 12-month cumulative probability of discontinuing oral ART after CAB/RPV was 19.9% (95% confidence interval [CI] 11.9-32.2%). After switching back to oral ART all individuals except one maintained or achieved HIV RNA levels below 50 copies/mL. CONCLUSION: These findings suggest that PWH who discontinue LA CAB/RPV and resume oral ART maintain or achieve high rates of virologic suppression.

International Journal of Infectious DiseasesVol. 168
Vita-Salute San Raffaele University (IT), University of Milan (IT), University of Pavia (IT), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Center for Prevention and Treatment of Infections (US), Azienda Ospedaliera San Gerardo (IT), Ospedale San Paolo (IT), ASST Fatebenefratelli Sacco (IT), University of Bari Aldo Moro (IT)
Gilead Sciences, ViiV Healthcare, Ministero della Salute
Zero hunger
Openalex Percentile: Top 24%
HIV/AIDS drug development and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.